ABBV dividend yield: 3.67%. MKC dividend yield: 4.00%. AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug. MKC is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in MKC shares.
AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.
MKC is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in MKC shares.
Is ABBV or MKC better for dividend income in 2026?
ABBV currently offers a 3.67% yield (6.20/share/year) while MKC offers 4.00% (2.00/share/year). MKC provides higher current income. However, ABBV has grown its dividend faster (8.9% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in ABBV vs MKC earn per year?
With $10,000 invested today: ABBV pays approximately $367/year. MKC pays approximately $400/year. With DRIP reinvestment over 10 years, these grow to $1,154/year (ABBV) and $899/year (MKC).
Does ABBV or MKC pay monthly dividends?
ABBV pays quarterly dividends. MKC pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this ABBV vs MKC comparison by email
Save your analysis + get weekly dividend insights. Free forever.